Research suggests that the histone methyltransferase SETD2 plays a role in cardiometabolic heart failure with preserved ejection fraction (HFpEF). SETD2 is implicated in chromatin rewiring, which may contribute to lipotoxic injury in this condition. The enzyme's involvement in HFpEF is being studied as a potential key factor in the disease.